Los Angeles Capital Management LLC Purchases 1,524 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Los Angeles Capital Management LLC grew its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 3.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 41,426 shares of the company’s stock after acquiring an additional 1,524 shares during the period. Los Angeles Capital Management LLC owned about 0.07% of Harmony Biosciences worth $1,309,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. boosted its position in shares of Harmony Biosciences by 16.9% during the first quarter. American Century Companies Inc. now owns 1,288,787 shares of the company’s stock valued at $42,775,000 after purchasing an additional 186,183 shares in the last quarter. LSV Asset Management raised its holdings in Harmony Biosciences by 25.0% in the first quarter. LSV Asset Management now owns 1,194,961 shares of the company’s stock worth $39,661,000 after purchasing an additional 238,744 shares in the last quarter. New Vernon Capital Holdings II LLC lifted its position in Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock valued at $16,211,000 after buying an additional 473,708 shares during the period. Capital Management Corp VA boosted its holdings in shares of Harmony Biosciences by 3.1% during the 2nd quarter. Capital Management Corp VA now owns 352,566 shares of the company’s stock valued at $11,141,000 after buying an additional 10,605 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Harmony Biosciences by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 271,435 shares of the company’s stock worth $8,577,000 after buying an additional 9,197 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Up 1.7%

NASDAQ:HRMY opened at $33.54 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75. The firm has a market cap of $1.93 billion, a P/E ratio of 10.55, a P/E/G ratio of 0.45 and a beta of 0.85. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.93. The firm has a 50-day simple moving average of $29.75 and a two-hundred day simple moving average of $32.79.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). The firm had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

HRMY has been the subject of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research note on Tuesday. Truist Financial began coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a “buy” rating and a $48.00 price objective on the stock. HC Wainwright decreased their target price on shares of Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. UBS Group dropped their price target on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Harmony Biosciences has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.